Evidence map›Paper›PMID 40038684›Full record

ArticleBMC cancer2025

Survival impact and risk factors of skeletal muscle loss during first-line EGFR-TKIs therapy in advanced lung adenocarcinoma patients.

Xin Nie, Mingzhu Zou, Chenhui Song, Ping Zhang, Di Ma, Di Cui, Gang Cheng, Lin Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xin Nie *Department of Medical Oncology Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, No. 1 Dahua Lu, Dongdan, Dongcheng District, Beijing, 100730, China.
Mingzhu Zou *Department of Radiology Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Chenhui Song *Chongqing Kingbiotech Corporation, Beijing, China.
Ping ZhangDepartment of Medical Oncology Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, No. 1 Dahua Lu, Dongdan, Dongcheng District, Beijing, 100730, China.
Di MaDepartment of Medical Oncology Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, No. 1 Dahua Lu, Dongdan, Dongcheng District, Beijing, 100730, China.
Di CuiDepartment of Pathology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Gang ChengDepartment of Medical Oncology Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, No. 1 Dahua Lu, Dongdan, Dongcheng District, Beijing, 100730, China.
Lin LiDepartment of Medical Oncology Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, No. 1 Dahua Lu, Dongdan, Dongcheng District, Beijing, 100730, China. lilin_51@hotmail.com.

Funding

National High Level Hospital Clinical Research Funding BJ-2023-073
6 · The paper itself

Abstract

purposeThe impact of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) on muscle mass in individuals with advanced lung cancer has yet to be fully delineated. This study aimed to examine the dynamics of skeletal muscle mass during EGFR-TKIs targeted therapy, elucidate its clinical relevance, and explore the potential mechanisms.

methodsWe retrospectively recruited 104 patients with EGFR-mutant advanced lung adenocarcinoma who received icotinib or afatinib as first-line treatment. Skeletal muscle changes were assessed by abdominal CT obtained before and during treatment with EGFR-TKIs. The mean interval (± SD) between two CT scans was 109 days (± 16 days). Targeted panel sequencing of tumor tissue was used to detect genetic alterations. Functional enrichment analysis of genes interacting with EGFR-TKIs and muscle loss was performed to elucidate the potential toxicological mechanisms.

resultsA total of 42 (40.4%) patients experienced muscle loss during targeted therapy. Genetic analysis indicated muscle loss group had a higher proportion of MDM2 amplification and PIK3CA alterations (p = 0.011 & p = 0.045, respectively).Patients with baseline low muscle density and experienced ≥ Grade 2 diarrhea had higher rate of muscle loss (p = 0.005 & p < 0.001, respectively). Multivariate analysis revealed that muscle loss was independently associated with shorter PFS (hazard ratio [HR] 1.86, 95% confidence interval [CI]: 1.09 ∼ 3.18; p = 0.023). Besides, we found genes associated with icotinib, afatinib and muscle loss were significantly enriched in MAPK signaling pathway and calcium signaling pathway.

conclusionsThis study highlights the high prevalence and detrimental impact of muscle loss during EGFR-TKIs treatment.

Indexed as

Adenocarcinoma of LungLung NeoplasmsMuscle, SkeletalProtein Kinase InhibitorsAdultAfatinibAgedAged, 80 and overCrown EthersErbB ReceptorsFemaleHumansMaleMiddle AgedMutationQuinazolinesAfatinibCrown EthersEGFR protein, humanErbB ReceptorsicotinibProtein Kinase InhibitorsQuinazolinesEpidermal growth factor receptor tyrosine kinase inhibitorsLung adenocarcinomaSkeletal muscle mass

Identifiers

PMID40038684
PMCPMC11881361

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.